Maxwell Luber

Treating Tourette’s Disorder

March 1, 2017

Melissa Fluehr, Maxwell Luber, and Barbara Coffey, MD, MS

Melissa Fluehr Clinical research coordinator, Behavioral Science Unit, Icahn School of Medicine at Mount Sinai, New York, NY. Ms. Fluehr has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity. Maxwell Luber Clinical research coordinator, Behavioral Science Unit, Icahn School of Medicine at Mount Sinai, New York, NY. Mr. Luber has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity. Barbara Coffey, MD, MS Director, National Tourette Center of Excellence, Icahn School of Medicine at Mount Sinai Dr. Coffey has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Tourette’s disorder (TD), also known as Tourette syndrome, is a fascinating yet complex neurodevelopmental disorder that can be challenging to treat. Dr. Georges Gilles de la Tourette, a French neurologist who described the first nine cases in 1885, had it right when he described the “peculiar” symptoms as a syndrome, later reporting that “fears, phobias, and arithmomania” were part of the picture.